newsfilter
← Latest News
PR Newswire·

Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe

  • Novavax received a $125 million milestone payment from Sanofi upon the initiation of the Phase 3 influenza-COVID-19 combination vaccine trial.
  • The trial, conducted in Europe, assesses the safety & immunogenicity of Novavax's Nuvaxovid combined with Sanofi's Efluelda/Fluzone High-Dose vaccine in adults aged 60 and older.
  • The global flu & COVID-19 markets currently exceed $10 billion in combined value.
  • The partnership has generated over $1 billion in revenue for Novavax to date.
  • Novavax is eligible for a $75 million milestone upon successful manufacturing technology transfer anticipated in mid-2027.
  • An additional $225 million milestone is payable upon a U.S. launch of the combination vaccine following successful clinical & regulatory completion.
  • The agreement includes royalties on Sanofi sales of Nuvaxovid, royalties for any combination products utilizing Nuvaxovid, & milestones plus royalties for new vaccines using Novavax's Matrix-M adjuvant.